|
LIVE WEBINAR: Tuesday, January 24, 2023, 5:00 PM – 6:00 PM Eastern Time (ET)
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology A Multitumor CME/MOC-Accredited Live Webinar Series
Join us on Tuesday, January 24th for this CME/MOC-accredited webinar Faculty
Michael J Birrer, MD, PhD Vice Chancellor, UAMS Director, Winthrop P Rockefeller Cancer Institute Director, Cancer Service Line Professor of Biochemistry and Molecular Biology Director’s Endowed Chair for the Winthrop P Rockefeller Cancer Institute University of Arkansas for Medical Sciences Little Rock, Arkansas
Kathleen N Moore, MD, MS
Associate Director, Clinical Research Virginia Kerley Cade Chair in Developmental Therapeutics Director, TSET Phase I Drug Unit Co-Director, Cancer Therapeutics Program Stephenson Cancer Center at the University of Oklahoma HSC Associate Director, GOG Partners Board of Directors, GOG Foundation Oklahoma City, Oklahoma Moderator Neil Love, MD Research To Practice Miami, Florida Tuesday, January 24, 2023 Topics to Be Discussed
Target Audience Learning Objectives
CE Credit Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Content Validation and Disclosures FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Birrer — Advisory Board: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Mersana Therapeutics Inc. Dr Moore — Advisory Committee: Aadi Bioscience, Alkermes, Aravive Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Clovis Oncology, Eisai Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Hengrui Therapeutics Inc, I-Mab Biopharma, ImmunoGen Inc, InxMed, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, Novartis, Onconova Therapeutics Inc, OncXerna Therapeutics Inc, Tarveda Therapeutics, Tesaro, A GSK Company, VBL Therapeutics, Verastem Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Verastem Inc; Contracted Research: GlaxoSmithKline, Lilly, Merck, PTC Therapeutics, Verastem Inc. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |